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Shock, regardless of etiology is characterized by decreased delivery of oxygen and nutrients to the tissues
and our interventions are directed towards reversing the cellular ischemia and preventing its conse-
quences. The treatment strategies that are most effective in achieving this goal obviously depend upon
the different types of shock (hemorrhagic, septic, neurogenic and cardiogenic). This brief review focuses
on the two leading etiologies of shock in the surgical patients: bleeding and sepsis, and addresses
a number of new developments that have profoundly altered the treatment paradigms. The emphasis
here is on new research that has dramatically altered our treatment strategies rather than the basic
pathophysiology of shock.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Hemorrhagic shock
Exsanguination is one of the leading causes of death following
trauma1,2 and prompt hemorrhage control along with adequate
ﬂuid resuscitation are the key components of early trauma care.
Similarly, hemorrhage is often encountered in non-trauma patients
as a complication following major surgeries. Despite hemorrhage
being a common problem, the optimal resuscitative strategy
remains controversial, with vigorous ongoing debates about issues
such as the type of ﬂuid, volume, rate, route of administration, and
endpoints of resuscitation.1.1. Futility of current methods/adverse effects of aggressive
resuscitation
Although it is widely believed that early aggressive ﬂuid resusci-
tation is beneﬁcial, clinical and basic science literature fails to provide
conclusive supporting evidence.3e7 As a matter of fact, the basic
rationale for administering intravenous ﬂuids in patients with
ongoing bleeding has been challenged repeatedly for almost a
century.8 Theoretically, ﬂuid resuscitation in the absence of (or prior
to) hemorrhage control canexacerbate bleedingdue to thedisruptionnd Surgical Critical Care,
el.: þ1 617 643 2433.
ciates Ltd. Published by Elsevier Ltof early soft thrombus, coagulopathy, and hemodilution.9e12 A
systematic review of 52 animal trials concluded that ﬂuid resuscita-
tion appeared to decrease the risk of death in models of severe
hemorrhage (RR¼ 0.48), but increased the risk of death in thosewith
less severe hemorrhage (RR ¼ 1.86).13 Furthermore, hypotensive
resuscitation (targeting a lower blood pressure), whenever tested,
reduced the risk of death (RR¼ 0.37). Similarly, a critical reviewof the
literature failed to ﬁnd any evidence that pre-hospital advanced life
support and improved outcomes in trauma patients.14 In a study that
has generated vigorous debate since its publication in 1994,15 hypo-
tensive patients with penetrating torso injury were randomized to
routineﬂuid resuscitation, or resuscitationwasdelayeduntil bleeding
hadbeen surgically controlled. The results of this study demonstrated
a survival advantage in the delayed resuscitation group (70% vs. 62%,
p ¼ 0.04). Despite all the controversy, the most impressive ﬁnding
remains that withholding ﬂuid resuscitation until hemorrhage
control did not increase themortality. The issue of timing and volume
of ﬂuid resuscitation in bleeding patients has also been addressed by
The CochraneDatabase of Systematic Reviews.16 Only six randomized
clinical trials met the inclusion criteria, and a careful review failed to
provide any evidence in support of (or against) early or large volume
intravenous ﬂuid administration in uncontrolled hemorrhage. Based
upon all this information, it is reasonable to conclude that ﬂuid
resuscitation is not a substitute for early hemorrhage control. Low
volume, careful resuscitation is reasonable, especially when trying to
get a dying patient to deﬁnitive care. However, early aggressive ﬂuid
resuscitation, in the absence to hemorrhage control, can’t be justiﬁed.d. All rights reserved.
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tation ﬂuids have profound cellular effects. It is now widely
recognized that resuscitation ﬂuids are not completely innocuous,
and they may actually potentate the cellular injury caused by
hemorrhagic shock.17 This concept of “resuscitation injury” has
steadily gained attention since a report by the Institute of Medicine
(1999) described in detail the wide spectrum of adverse conse-
quences that can follow resuscitative efforts.18 Historically, the
concept of large volume crystalloids resuscitation was a product of
seminal work by Shires, Moyer, Moss and others during the
1960s19e22 and it became common practice during the Vietnam
conﬂict. Their work suggested that infusion of large volume
isotonic crystalloids improved survival, and resuscitation ﬂuids
were needed not only to replace the intra-vascular volume loss, but
also to replenish interstitial deﬁcits. Therefore, these investigators
recommended ﬂuid replacement equal to three times the volume of
blood loss (and as high as 8:1 for severe shock). At that time the
emphasis was on restoration of intra-vascular and interstitial ﬂuid
deﬁcits, without much importance attached to the cytotoxic effects
of crystalloid ﬂuids. Isotonic ﬂuids were used widely in Vietnam
and it was during this period that the appearance of “shock lung/Da
Nang lung” (later termed acute respiratory distress syndrome or
ARDS) was ﬁrst described in soldiers that received massive crys-
talloid resuscitation. Today, ARDS and Multiple Organ Dysfunction
Syndrome aremajor causes of delayedmortality in trauma patients.
An ever-increasing basic science literature supports the new
paradigm that cellular injury is inﬂuenced not only by shock, but
also by our resuscitation strategies. Today, with the easy availability
of advanced cellular research techniques, we can study the effect of
resuscitation ﬂuids on the biological systems in much greater
detail. Review of the literature suggests that commonly used
resuscitation ﬂuids (especially racemic lactated Ringer’s solution)
can exaggerate the post trauma immune activation.23 Therefore, in
addition to the immediate side effects (worsening of hemorrhage),
delayed complications of ﬂuid resuscitation such as systemic
inﬂammatory response, ﬂuid overload (leading to compartment
syndromes, pulmonary edema etc), anemia, thrombocytopenia,
electrolyte/acid-base abnormalities, and cardiac and pulmonary
complications must also be kept in mind.24 Excessive ﬂuid resus-
citation increases the chances of developing abdominal compart-
ment syndrome in critically ill surgical/trauma, burn, and medical
patients.25e27 Similarly, in a multicenter study of burn patients,
administration of excessive ﬂuids (in excess of 25% of predicted)
increased the odds of ARDS (OR 1.7), pneumonia (OR 5.7), multiple
organ failure (OR 1.6), blood stream infections (OR 2.9), and death
(OR 5.3).28
1.2. New development
It is now being appreciated that resuscitation ﬂuids, like other
drugs, have indication for appropriate use, safe therapeutic doses,
potential side effects and complications. Despite a paucity of good
randomized controlled trials (RCT) in this arena, clinical practices
are rapidly changing. In general, large volume aggressive ﬂuid
resuscitation is becoming increasingly rare, and low volume,
carefully guided resuscitation is more common. A few of these
issues are discussed in more detail below:
i. Controlled hypotensive resuscitation: In appropriate patients
(e.g. in young victims of penetrating trauma) limiting the rate
andvolumeofﬂuidresuscitationprior tohemorrhage control is
rapidly becoming routine practice in large trauma centers.
Blunt trauma patients with associated head injury are still
resuscitated to a higher blood pressure, in an attempt to
maintain adequate cerebral perfusion, but early use of bloodproducts andvasopressors is replacing large volumecrystalloid
infusion. Prompted by the recommendations of some con-
sensus conferences29e32 and due to the unique logistical
challenges of the battleﬁeld, the resuscitation strategies being
utilized by the US military have changed dramatically: resus-
citation is selective, emphasizing low volume and practical
endpoints, and the use of ﬂuids with logistical advantages (e.g.
hetastarch) is preferred. The endpoint of resuscitation is not
a normal BP, but simply a palpable radial pulse and normal
mental status (in the absence of head injury). Thus, IVﬂuids are
given only selectively, and in much less volumes. Also, early
hemorrhage control is prioritized over aggressive ﬂuid resus-
citation. It is difﬁcult to determine the direct impact of these
new strategies on combat casualty outcomes, but is very
encouraging to note that for the ﬁrst time since the Crimean
War, the killed in action rate has markedly dropped below the
historic 20% to around 10e14%.33 Hypotensive resuscitation
can be performed by infusing ﬂuids to achieve a desired goal
(e.g. target blood pressure), or at a pre-determined ﬁxed rate.
Pre-clinical data shows that resuscitation to target mean arte-
rial pressure (MAP) of 40 mmHg, as opposed to 80 mmHg or
higher notonly results indecreasedblood loss but also inbetter
splanchnic perfusion and tissue oxygenation,34 less acidemia,
hemodilution, thrombocytopenia, and coagulopathy,35 decr-
eased apoptotic cell death and tissue injury35,36 and improved
survival.35,36 However, others have shown in large animal
models that prolonged duration (8 h) of hypotension increases
metabolic stress, tissue hypoxia, and mortality37,38 Still the
majority of the pre-clinical data favors MAPs between 40 and
60 mmHg or systolic blood pressure (SBP) between 80 and
90 mmHg. Furthermore, in each of these studies, hypotensive
resuscitationwithcrystalloidswasbeneﬁcial compared tonon-
resuscitated controls. An alternative means of hypotensive
resuscitation, particularly useful in pre-hospital or austere
environments where accurate blood pressure measurement
maynotbe feasible, is byﬂuid infusionat apre-determined rate
(carefully selected to avoid over resuscitation). In animal
studies, empiric rates of infusion have shown promise. Slow
infusion rates with crystalloid have been shown to reduce
organ injury,39 cause faster recovery of hemorrhage sup-
pressed cell mediated immune function40,41 and reduce
mortality. Overall, the data suggest that hypotensive resusci-
tation at a ﬁxed rate of 60e80 cc/kg/hour generally maintains
controlled hypotension to a SBP of 80e90 mmHg (MAP of
40e60 mmHg) and that this empiric control of infusion rates is
beneﬁcial in hemorrhagic shock. Regardless ofwhich approach
is selected (goal directed vs. ﬁxed volume), these pre-clinical
data combined with the clinical evidence15,16 argues strongly
against routine large volume crystalloid resuscitation. The best
approach for urban trauma services (short transport times)
appears to be “scoop and run”, where unnecessary ﬁeld inter-
ventions are avoided and the focus is on fast and efﬁcient
transport of the patient to the hospital.42
ii. Hypertonic saline: Another new development is the renewed
interest in hypertonic saline (HTS), not just as a volume
expander but also as an immunemodulator. The use of HTS for
resuscitation from hemorrhage was ﬁrst described in 1980,
when Velesco et. al,43 and DeFelippe et. al,44 reported in
separate studies that hypersomotic sodium chloride rapidly
expands plasma volume after major blood loss. Because of its
ability to mobilize interstitial ﬂuids into the vascular space,
250 ml of 7.5% saline can achieve results comparable to resus-
citation with 2e3 L of 0.9% saline. Since the original reports,
HTS or hypertonic saline combined with dextran (HSD) have
been tested in a number of RCTs, without showing a clear
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initial treatment for hypovolemic shock by reviewing the
original records from six trials (and 604 subjects).46 Overall
discharge survival rates were better with HSD resuscitation as
compared to conventional resuscitation.HSD resuscitationwas
particularly effective for the sub-group of patients that had
sustained head injury with a discharge survival rate of 38%, as
compared to a rate of 27% for the control group receiving saline.
All of these trials had used HTS as a volume expander, but
a more advantageous effect of HTS administration may be the
attenuation of immune mediated cellular injury. A number of
pre-clinical studies have demonstrated that HTS has the
potential to modulate the immune response, with an overall
attenuation of immune mediated cellular injury.47e56 A small
RCT has also shown that initial treatment of trauma patients
with HSD inhibits neutrophil adhesion molecule expression
and favorably modulates the inﬂammatory response.57 The
recently established Resuscitation Outcome Consortium
(ROC),58 funded by theNational Institutes of Health and the US
Department of Defense initiated two multicenter trials of
hypertonic resuscitation in blunt or penetrating trauma
patients in hypovolemic shock, and severe traumatic brain
injury. Both studies were designed to have three randomized
groups comparing hypertonic saline/dextran (7.5% saline/6%
dextran 70, HSD), hypertonic saline alone (7.5% saline, HTS),
and normal saline (NS) as the initial resuscitation ﬂuid for the
pre-hospital setting. In addition to the primary endpoints,
comprehensive data about the immunologic consequences of
hypertonic resuscitation would also be collected. Unfortu-
nately, the interim analysis of the data was not favorable, HTD
treated patients experienced higher early mortality and no
overall beneﬁt compared to the control arm (the full analysis
remain unpublished at the time of this writing).59 Despite the
much lauded laboratory effects of hypertonic saline, this ﬂuid
has not been the magic bullet hoped for by many researchers.
Based upon these clinical data, HTS cannot be recommended
for resuscitating trauma patients outside an approved trial.
Another ﬂuid that remains controversial is albumin. A recent
report [post hoc analysis of patients from the Saline versus
Albumin Fluid Evaluation (SAFE) study] suggests that albumin
should be avoided in patients with traumatic brain injury, as it
was associated with a signiﬁcant increase in mortality.60
iii. Damage control resuscitation: An idea that is gaining
momentum due to the ongoing war (Iraq and Afghanistan) is
the concept of hemostatic/damage control resuscitation.61
Trauma patients are often coagulopathic due to shock and
tissue injury, and this coagulopathy can be worsened by
resuscitation with crystalloids and packed red blood cells
(PRBC), as both are deﬁcient in clotting factors. Observational
data from civilian trauma centers and the battleﬁeld seem to
suggest that early administration of component therapy con-
taining fresh frozen plasma (FFP) and platelets may be bene-
ﬁcial.62,63 A recent retrospective analysis of mixed trauma
patients requiring surgery and massive transfusion compared
FFP:PRBC ratios of 1:1 and 1:4, and showed that only 26% of
patients treated with the former ratio died while 87.5% of
patients treated with the latter ratio died (p < 0.0001). In this
high risk groupwith an overallmortality of 55.5%, a 1:4 ratio of
FFP:PRBC increased the relative risk of dying by 18.9
(p < 0.001) when controlling for all other patient variables.64
Holcomb’s study of trauma patients at 16 trauma centers
who required massive transfusion found that an FFP:PRBC
ratio of 1:2 or higher (n ¼ 252) compared to lower ratios
(n¼214)was associatedwith improved30-daysurvival (59.6%
with high ratio vs. 40.4% with low ratio, p < 0.01).65 Theseconclusions have recently been questioned by a study that
suggests that the observed survival differences between
patients receiving high and low ratios in the ﬁrst 24 h may
simply be due to the fact that survivors live long enough to
receive component therapy (survivor bias).66 Based on the
battleﬁeld experience, the US Army has instituted a policy of
using a 1:1:1 ratio of PRBC:FFP:platelets in the battleﬁeld for
those that meet the criteria for massive resuscitation (expec-
ted to receive >10 units PRBC). However, no well-designed
randomized clinical trial has conclusively identiﬁed the
optimal ratios of blood components. Our own institutional
policy is to start FFP infusion as early as possible in massively
bleeding patients, by activatingMassive Transfusion Protocols
(MTP)whichdeliverPRBC:FFP in a ratio of 2:1, and administers
6 units of platelets for 10 units PRBC. Despite an ongoing
debate about the precise ratios, there is general agreement
that the blood products should be administered in the form of
an MTP to optimize the processes of care and to improve
outcomes. Theoftendisorganizedprocess of blood component
transfusion in the faceofmassivehemorrhagebeneﬁts froman
organizedand standardizedapproach thatdelivers theneeded
blood products while avoiding their misuse. Despite these
obvious attractive features, in a recent review Malone found
only 10 such protocols published worldwide.67 The utility of
MTP (using different ratios of blood components) has already
been veriﬁed in some case controlled studies. Cotton tested
the effectiveness of a Trauma Exsanguination Protocol (1:2:4
ratio of platelets:FFP:PRBC) by comparing patients treated
with theprotocol (n¼94over18months) to a cohort of similar
patients admitted during the prior 18 months (n ¼ 117). The
study found that implementation of the protocol reduced 30-
daymortality (51% vs. 66%, p< 0.03), decreased intraoperative
crystalloid administration (4.9 L vs. 6.7 L, p ¼ 0.002), and
reduced post-operative blood product use (2.8 units PRBCs vs.
8.7 units, p < 0.001; 1.7 units FFP vs. 7.9 units, p < 0.001; 0.9
units platelets vs. 5.7 units, p < 0.001).68 Dente conducted
a similar studyof anMTP (1:1:1 ratio of platelets:FFP:PRBC), by
comparing matched patients during one year period before
and after implementation of protocol (73 protocol, and 84
matched controls). Implementation of the protocol was found
to reducemortality in the ﬁrst 24 h (17%withMTP vs. 36% pre-
MTP, p ¼ 0.008), and at 30 days (34% vs. 55%, p ¼ 0.04), with
amorepronounced impact in theblunt traumapatients.69 This
study also showed that MTP patients required fewer overall
transfusions of PRBCs and FFP after the ﬁrst 24 h (2.7 units
PRBCS vs. 9.3 units, p < 0.0001; 3 units FFP vs. 7.5 units,
p < 0.05). While further prospective research is needed to
specify the exact ratios, there is convincing evidence that
implementation of standardized protocols for blood compo-
nent transfusion improves processes of care, reduces overall
use of blood components, and improves outcomes.
iv. Red blood cell substitutes: Although advances in viral
screening have markedly decreased the risks of infectious
transmissions, blood transfusion continues to be associated
with numerous serious side effects. In trauma patients, trans-
fusionof redbloodcells (especiallyafterprolonged storage)has
been shown to disturb the immune system with an early
immune activation resulting in Systemic Inﬂammatory
ResponseSyndrome (SIRS), andadelayed immunesuppression
which predisposes the patients to infections.70 As a matter of
fact, transfusion of PRBC remains an independent risk factor for
increased infections, multiple organ failure, length of hospital
stay, and mortality.71e74 This has prompted many researchers
to focus their attention on testing alternative oxygen carrying
solutions.75 A detailed discussion about the history and the
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article. However, all of these solutions contain some form of
polymerized hemoglobin molecule and are thus labeled as
hemoglobin-based oxygen carriers (HBOC). A common
problemwith theHBOC relates to the scavengingof nitric oxide
by the free hemoglobin molecule, which results in severe
vasoconstriction, a pro-inﬂammatory response, andend-organ
injury. Different formulations differ in the mammalian source
of the hemoglobin and how it is cross-linked, as well as in
storage and length of shelf-life. Of the HBOCs tested thus far,
only Hemopure or HBOC-201 (13 g/dL glutaraldehyde poly-
merized bovine hemoglobin) has remained in contention for
possible human use, while other formulations such as Poly-
heme (10 g/dL glutaraldehyde polymerized human hemo-
globin) and HemAssist (10 g/dL diaspirin cross-linked human
hemoglobin) have fallen out of favor due to negative phase III
clinical trials. In Sloan’s multicenter randomized clinical trial
(RCT) trauma patients in severe hemorrhagic shock received
either 500 ml of saline (n ¼ 53) or HemAssist (n ¼ 58) within
60 min of presentation. The study found a higher 28-day
mortality in the treatment arm (47% for HemAssist vs. 25% for
saline, p ¼ 0.015).76 In another multicenter RCT, trauma
patients with severe hypovolemic shock were randomized to
standard of care (n ¼ 62) or HemAssist (n ¼ 53) without any-
difference in 5- or 28-day mortality.77 Similar ﬁndings were
reported with Polyheme in a subsequent RCT, where trauma
patients in severe hemorrhagic shock were given either stan-
dard of care (crystalloid and allogenic blood transfusion,
n ¼ 365) or up to 6 units of Polyheme (n ¼ 349). Even after
accounting for numerous protocol violations (17%), there was
nomortality beneﬁt in the treatment arm, and a higher rate of
adverse events (93% for Polyheme vs. 88% for controls,
p¼ 0.041).78 A 2008meta-analysis of 16 HBOC trials, including
four trials of traumapatients receivingHemAssist or Polyheme,
raised alarm as patients receiving HBOCs were noted to have
a signiﬁcant risk of myocardial infarction (RR, 2.71; 95% CI,
1.67e4.40), and mortality (RR, 1.30; 95% CI, 1.05e1.61).79 This
meta-analysis also included a single study data from a 2005
presentation to theU.S. FoodandDrugAdministration (FDA)on
HBOC-201 use in surgical patients. HBOC-201 (Hemopure) has
also been rested in a trauma patient population in South
African study but the ﬁnal results of this trial remain unpub-
lished.80HOC201hasbeenextensively testedwithgoodresults
in animal models (and is approved for veterinary use). It has
also been tested in a large phase III clinical trial (n-688) in
elective orthopedic surgical patients, where use of HBOC-201
resulted in less need for PRBC transfusion but a signiﬁcant
increase in serious adverse events.81Aphase IImulticenter trial
in trauma patients entitled Restore Effective Survival in Shock
(RESUS) was ﬁrst submitted to the FDA for approval in 2005.
However, after an initial positive response the FDA has
repeatedly refused to allow the clinical trial to proceed due to
concerns about patient safety, despitemultiple revisions in the
study protocol. Thus, based upon these current data, the use of
any HBOCs can’t be endorsed at this time outside of well-
designed, thoroughly vetted clinical trials.
2. Septic shock
2.1. Initial resuscitation
As opposed to hemorrhagic shock, early goal directed resuscita-
tion has been shown to improve 28-day mortality in a single center,
prospective, RCT.82 Although the exact parameters used to guide
resuscitation in that studyhavebeen challenged, thebasic concept isclearly sound, as has been validated by a number of subsequent
studies.83e87 For optimal results, the resuscitation protocol must be
initiated as soon as shock is diagnosed and should not be delayed
until admission to the intensive care unit (ICU). Due to venous
dilation, and increased capillary leak, most of these patients require
aggressive ﬂuid resuscitation over the ﬁrst 24 h. During this period,
in addition to ensuring adequate cardiac pre-load (e.g. central
venous pressure, pulmonary artery occlusion pressure), parameters
of tissue perfusion and oxygen delivery (e.g. serum lactate, base
deﬁcit, urine output, central/mixed venous oxygen saturation,
cardiac output) should be carefullymonitored. The SAFE study88 has
shown that albumin and crystalloids are equally safe and effective
(except for patients with traumatic head injury). Surviving Sepsis
Campaign has recently reviewed the literature and published
updated and comprehensive guidelines to guide the resuscitation in
adult and pediatric patients.89These guidelines also provide
evidence-based recommendations regarding a wide spectrum of
supportive/adjunctive therapies (e.g. glycemic control, steroids,
vasoactive agents, activated protein C etc).
2.2. Vasopressors and inotropes
Within reasonable limits, blood ﬂow through the tissue beds is
more important than blood pressure. However, during septic shock
autoregulation is not normal and perfusion can become linearly
dependent on blood pressure. Thus, after the initial ﬂuid resusci-
tation (or concomitantly) hypotensive patients may require
administration of vasopressors to keep the mean arterial pressure
>65 mmHg (which has been shown to preserve tissue perfu-
sion).90,91 Whenever possible, vasopressors should be started after
providing adequate initial ﬂuid resuscitation. There is no compel-
ling, high quality evidence that shows one agent to be superior to
another.92 However, Surviving Sepsis Campaign recommends
“norepinephrine or dopamine as the ﬁrst choice vasopressor agent
to correct hypotension in septic shock (Grade IC)”.89 According to
them, norephephrine has some attractive features as it increases
MAP (due to vasoconstriction), with little change in heart rate and
some increase in stroke volume. Dopamine is another good choice,
which increases MAP and stroke volume. However, it also increases
heart rate, which may not be desirable. Other choices have some
unattractive features. For example epinephrine can cause tachy-
cardia, decreased splanchnic circulation, and hyperlactemia.
Phenylephrine is a pure vasopressor and is least likely to cause
tachycardia, but it decreases stroke volume. Vasopressin has
recently gained popularity for treating refractory hypotension in
septic shock patients, as there is a relative deﬁciency of this
hormone in septic shock.93 However, a recent RCT-Vasopressin and
Septic Shock Trial (VASST), which enrolled 778 patients failed to
show a survival advantage of vasopressin (0.03 units/min) over
norepinephrine, or a reduction in overall rate of serious adverse
events.94 In addition to agents that restore the vascular tone,
patients with documented or suspected decrease in cardiac func-
tion (elevated ﬁlling pressures and low cardiac output) should be
given dobutamine as an inotropic agent.89 Administration of these
agents should be guided by serial measurements of markers of
tissue oxygenation, ﬁlling pressures and cardiac output, without
making an attempt to achieve supra-normal levels.89
2.3. Blood products
The optimal hemoglobin level has not been determined for
severely septic patients. Rivers and associates in the early goal
directed therapy trial82 used a target hematocrit of 30% in patients
who continued to show low central venous oxygen saturation. In
a more recent multi-institutional trail of mixed ICU patients (not
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and 10e12 gm/dL were associated with identical outcomes.95 Thus,
it is reasonable to aim for target hemoglobin between 7 and 9 gm/
dL if parameters of tissue oxygenation are adequate. But in cases of
depressed tissue oxygenation or in patients with other co-morbid
issues (e.g. coronary artery disease, stroke, etc), hemoglobin levels
can be pushed up to 10e12 gm/dL to optimize the tissue oxygen
delivery. However, this area remains controversial and evidence-
based guidelines have been proposed by experts in the ﬁeld to steer
the transfusion practices in these critically ill patients.96
3. Future directions
A number of new and exciting developments in the arena of
resuscitation research have the potential of radically transforming
clinical care in the near future. Two such areas of research are
discussed here:
3.1. Pharmacologic therapy
Over the years, a number of pharmacologic agents have been
tested as possible adjuncts to ﬂuid resuscitation. These drugs cover
a wide spectrum including neuroendocrine agents, calcium channel
blockers, ATP-pathway modiﬁers, prostaglandins, sex steroids, anti-
oxidants, anti-inﬂammatory agents, and immune-modulators.
Although there is strong laboratory evidence of their beneﬁcial
effects on tissue perfusion, myocardial contractility, reticulo-endo-
thelial function, cell survival, oxidative injury, and immune activa-
tion, majority of these agents are not yet in clinical use as
resuscitative agents. A thorough discussion of the research in this
area is beyond the scope of this article. However, a number of agents
aimed at correcting the circulatory and immunologic derangements
of hemorrhage are worth mentioning as promising pharmacologic
adjuncts to resuscitation.Dr. Chaudry’s grouphasextensively studied
the role of sex steroids in cytokine responses and neutrophil adhe-
sion after hemorrhage; they have proposed estrogen and its analogs
as possible beneﬁcial treatments.97 Dr. Coimbra’s group has studied
thephosphodiesterase inhibitor, pentoxyfylline, alreadywidely used
for vascular disease due to its rheologic properties, as a treatment for
hemorrhagebecause it reducesneutrophil activationandadhesion.98
A Cochrane review recently analyzed data on the opiate antagonist
Naloxone which has been studied based on the ﬁnding that central
Mu, Epsilon, Kappa, and Delta receptors are activated during
hemorrhagic shock and inhibit Caþþ channels; the data suggested
that further clinical trials are needed to determine if the beneﬁcial
effects on blood pressure by administration of Naloxone result in any
durable improvements in survival.99 A common thread across all of
these potential agents is that they are already inwide clinical use for
other disorders. Thus, there is great hope that with more clinical
evidence, these agents whose safety proﬁle has already been tested
for various non-trauma indications can be rapidly implemented as
adjuncts to ﬂuid resuscitation. Our group has been studying another
group of drugs, also already in wide clinical use for non-trauma
indications, in animal models of shock. Following hemorrhage, the
stress of shock and resuscitation causes an immediatemodulation of
genes and proteins involved in a variety of cellular defense pathways
through an alteration in their acetylation status.100,101 We hypothe-
sized that histonedeacetylase (HDAC) inhibitors such as valproic acid
(VPA) and suberoylanilide hydroxamic acid (SAHA) may have utility
in the treatment of shock through restoration of normal cellular
acetylation. We subsequently have shown that HDAC inhibitors
rapidly reverse shock induced alterations, restore normal histone
acetylation, and improve survival in different models of otherwise
fatal hemorrhagic shock and poly-trauma.102e104 Impressively, this
survival improvement was achieved without conventional ﬂuidresuscitation or blood transfusion, which makes this approach very
appealing for the logistically constrainedpre-hospital and battleﬁeld
environments. It appears that HDAC inhibitors rapidly activate
nuclear histones as well as numerous cellular proteins to create
a “pro-survival” phenotype in hemorrhagic and septic shock.105e109
Unpublished data also demonstrate that this approach is very
promising for the treatment of traumatic brain injury. A number of
these HDAC inhibitors are currently being tested in phase I and II
clinical trials (non-traumatic situations). We believe that additional
research in this arena could ultimately lead to a potent pharmaco-
logic adjunct to the treatment of hemorrhagic shock that works by
promoting cell survival during periods of lethal stress.
3.2. Emergency Preservation and Resuscitation (EPR)
Up to 80% of trauma deaths occur in the early post-traumatic
phase,110 with exsanguination as the dominant etiology.2 Profound
shock from blood loss does not respond well to conventional
methods of resuscitation.14 Evenwhen the underlying cause can be
treated and circulation restored, cerebral ischemia lasting 5 min or
longer invariably results in severe brain damage. Often the under-
lying injuries are reparable but the patient dies of irreversible shock
or severe brain damage. In this setting, strategies to maintain cere-
bral and cardiac viability long enough to gain control of hemorrhage
and restore intra-vascular volume could be life saving. This requires
an entirely new approach to the problem, with emphasis on rapid
total body preservation, repair of injuries during metabolic arrest,
and controlled resuscitation: Emergency Preservation and Resusci-
tation (EPR). Currently, hypothermia is themosteffectivemethod for
preserving cellular viability during prolonged periods of ischemia.
Although, no clinical studies have been conducted to test the ther-
apeutic beneﬁts of hypothermia in trauma patients, numerouswell-
designed pre-clinical studies clearly support this concept. It should
be emphasized upfront that induced hypothermia and hypothermia
secondary to shock are very different entities. Induced hypothermia
is therapeutic in nature whereas hypothermia, seen in severely
traumatized patients, is a sign of tissue ischemia and failure of
homeostatic mechanisms to maintain normal body temperature. It
is clear from the literature that rapid induction of deep/profound
hypothermia (<15 C) can improve otherwise dismal outcome after
exsanguinating cardiac arrest.111e113 Depending on the degree of
hypothermia, good outcomes have been achieved with cardiac
arrests of 15, 20, 30 and even 90 min in canine models.114,115
Furthermore, the period of hypothermia can be safely extended to
180 min if blood is replaced with organ preservation ﬂuids and low
ﬂow cardiopulmonary bypass is continued (as opposed to no ﬂow)
during the arrest period.116 Although ground breaking, the clinical
relevanceof theseoriginal studieswas somewhat limitedby reliance
on pressure-controlled models of hemorrhagic shock (or no
hemorrhage), an absence of major injuries, and lack of surgical
interventions. To ﬁll these gaps, our team has utilized clinically
realistic large animal models of lethal vascular injuries and soft
tissue trauma to demonstrate that profound hypothermia can be
induced through an emergency thoracotomy approach for total
body protection, with excellent long-term survival and no neuro-
logical damage or signiﬁcant organ dysfunction.117 In a follow up
study, it was established that lethal vascular injuries, above and
below the diaphragm, can be repaired under hypothermic arrest
with >75% long-term survival.118 More importantly, it was shown
that hypothermia could be used successfully even after 60 min of
normothermic shock (transport time), and that the surviving
animals were not only neurologically intact but also had normal
cognitive functions. Subsequent studies have determined that to
achieve the best results, profound hypothermia must be induced
rapidly (2 C/min) and reversed at a slower rate (0.5 C/min).119,120
H.B. Alam / International Journal of Surgery 9 (2011) 5e1210Induction of hypothermia has been shown to preserve various cell
types in the central nervous system, while providing some immu-
nological advantages, andmodulating cell survival pathways.121e123
The optimal depth of hypothermia is 10 C, and decreasing the
temperature to ultra-profound levels (5 C)mayactuallyworsen the
outcome.124 If done appropriately, the safe duration of total body
preservation in poly-trauma is about 60 min,125 and it results in no
increase in post-operative bleeding or septic complications.126
Technically it is now feasible to induce hypothermia using small,
battery operated, portable equipment (suitable for austere settings
and pre-hospital environment).127 This is associated with excellent
“total body preservation” which may have signiﬁcant implications
not only for treatment of traumatic injuries but also for preserving
organs for transplant.128 Induction of hypothermia not only modu-
lates metabolism but also inﬂuences a vide variety of cellular and
sub-cellular mechanisms,129 including alteration in transcription of
numerous beneﬁcial genes,130 the down-stream effects of which
persists long after hypothermia. There is also some data from small
animal models to suggest that similar metabolic arrest (and tissue
preservation) can be achieved with other methods, such as inhaled
hydrogen sulﬁde.131 It may sound futuristic, but the expertise to
preserve the viability of key organs during repair of otherwise lethal
injuries is now available,132 and a prospective multi-institutional
clinical trial is scheduled to start later this year.133
4. Conclusions
Treatments of shock have evolved over the last 50 years, but the
changes over the last decade have been especially dramatic.134e136
Based upon contemporary data, early goal directed ﬂuid resuscita-
tion shouldbe considered the standardof care for septic shock, along
with additional supportive measures as advocated by the Surviving
Sepsis Guidelines.89 The optimal approach for hemorrhagic shock is
not as clear due to a relative paucity of level-1 evidence. However,
according to my personal opinion the existing literature strongly
supports some common sense recommendations for the treatment
of hemorrhagic shock.137 First, resuscitation is not a substitute for
early hemorrhage control. From the moment of injury, all efforts to
provide deﬁnitive control of hemorrhage as expeditiously as
possible must be aggressively pursued. Second, large volume crys-
talloid resuscitation is deleterious and should be abandoned. Fluid
resuscitation can be safely withheld in patients who have adequate
cerebral perfusion (normal mental status in the absence of head
injury) and a palpable radial pulse, especially if the pre-hospital
transport time is expected to be brief. For situations where the time
to deﬁnitive care is longer than 15e20 min, initiation of limited
volume resuscitation is supported by the literature. Speciﬁcally, the
goals should be to maintain either a SBP approximating
80e90mmHg, or clear mental status (in the absence of head injury)
and a palpable radial pulse. At present, it seems that infusion of
lactated Ringer’s solution (containing only the L-isomer of lactate) is
the best option in the pre-hospital setting, whereas early use of
blood products should be strongly considered once the patient
reaches the hospital.18,23,137 While the ideal ratio of blood compo-
nents is under investigation, there is a strong trend in favor of
starting component therapy early and to administer higher ratios of
FFP and platelets to PRBC. Newer methods for blood component
preservation have improved their logistical proﬁle, whichmay yield
shelf-stable products for pre-hospital use in the near future.138,139
The evidence strongly suggests that applying these ratios through
an institutional protocol improves delivery of care and outcomes.
When blood products are not an option, blood substitutes may have
a role. However, at present, the data on blood substitutes are far too
mixed to recommend their use outside of trials. Finally, pharmaco-
logic adjuncts to resuscitationmay ultimately play a role is reducingthe deleterious immunologic and cellular effects of hemorrhage and
resuscitation. This is an exciting area of future research but their use
remains to be validated in robust clinical trials. For now, early and
expeditious control of hemorrhage and modest, goal directed
resuscitation should be the standard of care.
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